Parkinson’s Disease Therapeutics Market to Record an Exponential CAGR by 2025

The global Parkinson’s Disease Therapeutics Market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025, according to a new report titled “Parkinson’s Disease Threapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research (TMR) (. The report states that high prevalence of Parkinson’s disease, rise in geriatric population across the globe, increase in funding for clinical research and grants, etc. are expected to spur the growth of the Parkinson’s disease therapeutic drugs during the forecast period, i.e. 2017 to 2025.

North America and Europe are projected to dominate the global Parkinson’s disease therapeutics market in the near future, primarily due to the large base of aging population, high clinical R&D budget to address the unmet needs of Parkinson’s disease, and increase in awareness regarding the disease in these regions. Europe is estimated to dominate the global Parkinson’s disease therapeutics market by the end of 2025, which can be ascribed to the high prevalence and rise in incidence rate of Parkinson’s disease in the developed countries in the region such as Germany, France, the U.K., and Italy, promising product pipeline, and various initiatives undertaken by the government and non-profit organizations to promote awareness regarding the disease. The Parkinson’s disease therapeutics market in Europe is expected to witness the highest CAGR of more than 11.0% from 2017-2025.

Parkinson’s disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. The exact cause of Parkinson’s disease is not known. It is largely prevalent among the geriatric population. Classifying by gender, men are one-and-half times more affected by the disease than women. According to the Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by Parkinson’s disease and around 1 million Americans are living with it.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26975

However, the exact number of patients suffering from Parkinson’s disease is known due to incompleteness and inconsistency in the prevalent studies and underdiagnosed cases. According to the Global Burden of Disease Study, it is estimated that around 13 million people will be affected by Parkinson’s disease worldwide by the year 2040. China has the world’s largest population affected with Parkinson’s disease, which is an estimated 2.5 million people, and the number is likely to become double by the end of 2030, accounting for half of the world’s population suffering from the disease. The rapidly growing geriatric population, coupled with high prevalence and increasing incidence rate of Parkinson’s disease in the developed countries, is projected to a key driving factor of the Parkinson’s disease therapeutics market during the forecast period.

In terms of route of administration, the oral route is projected to dominate the global Parkinson’s disease therapeutics market during the forecast period and is estimated to expand at a CAGR of more than 7.5% from 2017-2025. More than 70% of the drugs available for treatment of Parkinson’s disease are in the tablet and capsule form. Some of the drugs are orally disintegrated. However, the estimated launch of sublingual film by SUNOVION and inhaled formulation by Acorda Therapeutics, Inc. during the forecast period is likely to gain market exceeding 15% by the end of 2025. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson’s disease are estimated to limit the growth of the oral route of administration segment by the end of 2025.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26975

Among distribution channels, the retail pharmacy segment is projected to hold the dominant share of the global Parkinson’s disease therapeutics market during the forecast period and is likely to expand at CAGR of more than 11% from 2017 to 2025. Easy availability of Parkinson’s therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The hospital pharmacy segment is the second leading shareholder of the global Parkinson’s disease therapeutics market. However, the segment is likely to lose its market share by the end of 2025. Intestinal infusion drugs and subcutaneously administered drugs, and certain patented drugs, to an extent, have contributed to the key market share of the hospital pharmacy segment in 2016. The online pharmacy segment is poised to grow at as significant CAGR of more than 12% during the forecast period.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.